Although its clinical trial in patients with solid tumors (NCT00661414) did not meet the primary endpoint of progression‐free survival (PFS) and led to peripheral blood lymphocytopenia.[225, 226] ABC294640, a selective SphK‐2 inhibitor, has exhibited significant inhibition of tumor growth in preclinical mouse studies and is presently under investigation for hepatocellular carcinoma (HCC), diffuse large B‐cell lymphoma (DLBCL), Kaposi sarcoma, and other malignancies.[227, 228]. This evidence concerns the gene SPHK2 and hepatocellular carcinoma.